Explore the PTAB proceeding IPR2025-00874 filed by Aquestive Therapeutics, Inc. against Iono Pharma, LLC on May 16, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2025-00874
Filing Date
May 16, 2025
Petitioner
Aquestive Therapeutics, Inc.
Respondent
Iono Pharma, LLC
Status
Pending
Respondent Application Number
16347625
Respondent Tech Center
1600
Respondent Patent Number
11021437

Proceeding Decision New

Decision pending - set alert to receive updates

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

EX2001

Aug 18, 2025EXHIBITPATENT OWNER

EX2002

Aug 18, 2025EXHIBITPATENT OWNER

EX2003

Aug 18, 2025EXHIBITPATENT OWNER

EX2004

Aug 18, 2025EXHIBITPATENT OWNER

EX2005

Aug 18, 2025EXHIBITPATENT OWNER

EX2006

Aug 18, 2025EXHIBITPATENT OWNER

EX2007

Aug 18, 2025EXHIBITPATENT OWNER

EX2008

Aug 18, 2025EXHIBITPATENT OWNER

EX2009

Aug 18, 2025EXHIBITPATENT OWNER

EX2010

Aug 18, 2025EXHIBITPATENT OWNER

EX2011

Aug 18, 2025EXHIBITPATENT OWNER

EX2012

Aug 18, 2025EXHIBITPATENT OWNER

EX2013

Aug 18, 2025EXHIBITPATENT OWNER

EX2014

Aug 18, 2025EXHIBITPATENT OWNER

EX2015

Aug 18, 2025EXHIBITPATENT OWNER

EX2016

Aug 18, 2025EXHIBITPATENT OWNER

EX2017

Aug 18, 2025EXHIBITPATENT OWNER

EX2018

Aug 18, 2025EXHIBITPATENT OWNER

EX2019

Aug 18, 2025EXHIBITPATENT OWNER

EX2020

Aug 18, 2025EXHIBITPATENT OWNER

Patent Owner's Discretionary Denial Brief

Aug 18, 2025PAPERPATENT OWNER

EXPUNGED

Jun 18, 2025PAPERBOARD

Notice: Notice filing date accorded

Jun 18, 2025PAPERBOARD

Notice: Patent Owner's Mandatory Notice

Jun 18, 2025PAPERPATENT OWNER

Notice: Patent Owner's Power of Attorney

Jun 18, 2025PAPERPATENT OWNER

Almoazen '437 Patent, U.S. Patent No. 11,021,437 B2.

May 16, 2025EXHIBITPETITIONER

Truelove 1, U.S. Patent No. 3,809,714

May 16, 2025EXHIBITPETITIONER

Ashraf, “Considerations in Developing Sublingual Tablets – An Overview"

May 16, 2025EXHIBITPETITIONER

Fuchs, U.S. Patent No. 4,136,145.

May 16, 2025EXHIBITPETITIONER

Almoazen '437 Patent File History, U.S. App. Ser. No. 16/347,625.

May 16, 2025EXHIBITPETITIONER

Truelove 2, U.S. Patent No. 3,825,583.

May 16, 2025EXHIBITPETITIONER

Truelove 4, “Prodrug Approaches to , , , Novel Epinephrine Prodrug”

May 16, 2025EXHIBITPETITIONER

Truelove 3, U.S. Patent No. 3,868,461.

May 16, 2025EXHIBITPETITIONER

The Merck Index, 12th Ed., 1996, p. 613.

May 16, 2025EXHIBITPETITIONER

USP certificate for epinephrine, dated 14 Aug 2017.

May 16, 2025EXHIBITPETITIONER

EpiPen Information

May 16, 2025EXHIBITPETITIONER

Almoazen ‘437 Patent Provisional Application, Ser. No. 62,421,316.

May 16, 2025EXHIBITPETITIONER

Almoazen PCT Application, WO2018/089570 A1 (PCT/US2017/060761).

May 16, 2025EXHIBITPETITIONER

Florence, “Physicochemical Principles of Pharmacy”.

May 16, 2025EXHIBITPETITIONER

Bodor, U.S. Patent No. 4,145,441.

May 16, 2025EXHIBITPETITIONER

Rawas-Qalaji, U.S. Patent Application Publication No. US 2007/0202163 A1.

May 16, 2025EXHIBITPETITIONER

Ettmayer, “Lessons Learned from Marketed and Investigational Prodrug".

May 16, 2025EXHIBITPETITIONER

Rautio, “Prodrugs: design and clinical applications”.

May 16, 2025EXHIBITPETITIONER

Silverman, “Prodrugs and drug delivery systems”.

May 16, 2025EXHIBITPETITIONER

Schobel, U.S. Patent No. 11,191,737 B2.

May 16, 2025EXHIBITPETITIONER

Almoazen Paper, “Development of a fast dissolving film of epinephrine ...".

May 16, 2025EXHIBITPETITIONER

Baldessarini, “Hydrolysis of diester prodrugs of apomorphine”.

May 16, 2025EXHIBITPETITIONER

Kristoffersson, “Drug latentiation of terbutaline”.

May 16, 2025EXHIBITPETITIONER

Christrup, “Improvement of buccal delivery ... using the prodrug approach”

May 16, 2025EXHIBITPETITIONER

Lieberman, “The diagnosis and management of anaphylaxis practice parameter"

May 16, 2025EXHIBITPETITIONER

den Daas, “Improvement of the oral bioavailability . . . ester prodrugs".

May 16, 2025EXHIBITPETITIONER

Hansen 1991, “Ketobemidone prodrugs for buccal delivery”.

May 16, 2025EXHIBITPETITIONER

Hansen 1992, “Ketobemidone prodrugs for buccal delivery ...".

May 16, 2025EXHIBITPETITIONER

Markup of EX1001 showing EX1022 contribution.

May 16, 2025EXHIBITPETITIONER

Roche, “Design of biopharmaceutical properties through prodrugs ...".

May 16, 2025EXHIBITPETITIONER

Markup of EX1022 showing material found in EX1001.

May 16, 2025EXHIBITPETITIONER

Morrison and Boyd, “Organic Chemistry”, Sections 18.1-18-4.

May 16, 2025EXHIBITPETITIONER

Streitwieser, “Introduction to Organic Chemistry”, excerpts.

May 16, 2025EXHIBITPETITIONER

Stepensky, “Long-Term Stability Study of L-Adrenaline Injections ...".

May 16, 2025EXHIBITPETITIONER

Rautio II, “Prodrugs—from Serendipity to Rational Design”.

May 16, 2025EXHIBITPETITIONER

Senel, “Drug permeation enhancement via buccal route ...".

May 16, 2025EXHIBITPETITIONER

Kohn, “Clinical Comparison of Dipivalyl Epinephrine and Epinephrine ...".

May 16, 2025EXHIBITPETITIONER

Journal of Medicinal Chemistry (JMC) Manuscript Requirements

May 16, 2025EXHIBITPETITIONER

Declaration of Jarkko Rautio, Ph.D.

May 16, 2025EXHIBITPETITIONER

Declaration of Nicholas A. Meanwell, Ph.D.

May 16, 2025EXHIBITPETITIONER

Notice: Power of Attorney

May 16, 2025PAPERPETITIONER

Petition: as filed

May 16, 2025PAPERPETITIONER